Deutsche upgrades GSK after strategy day
24th Jun 2021 10:16
(Sharecast News) - Deutsche Bank upgraded GlaxoSmithKline to 'hold' and raised its target price on the drugmaker's shares after it set out strategic targets.
Read moreGSK sets out ten-year vision, targets sales of £33bn
23rd Jun 2021 12:51
(Sharecast News) - GlaxoSmithKline is targeting annual sales of more than £33bn once its consumer healthcare arm has been spun out, as it refocuses on vaccines and speciality medicines, the drugs giant announced on Wednesday.
Read moreGSK's ViiV signs deal to develop longer-acting HIV drugs
22nd Jun 2021 07:46
(Sharecast News) - GlaxoSmithKline announced on Tuesday that its majority-owned HIV specialist ViiV Healthcare has signed a collaboration and licence agreement with Halozyme Therapeutics, giving it exclusive access to its 'ENHANZE' drug delivery technology, recombinant human hyaluronidase PH20 enzyme (rHuPH20), for specific targets used in the treatment and prevention of HIV.
Read moreMonday broker round-up
21st Jun 2021 13:05
(Sharecast News) - SSE: Jefferies downgrades to hold with a target price of 1,680p.
Read moreWednesday broker round-up
16th Jun 2021 12:50
(Sharecast News) - Pets At Home: Berenberg reiterates buy with a target price of 540p.
Read moreTuesday broker round-up
15th Jun 2021 13:39
(Sharecast News) - Page Group: Morgan Stanley downgrades to underweight with a target price of 545p.
Read moreMonday broker round-up
14th Jun 2021 13:49
(Sharecast News) - Serco: Numis upgrades to buy with a target price of 180p.
Read moreGlaxoSmithKline teams up with iTeos to develop cancer drug
14th Jun 2021 13:38
(Sharecast News) - GlaxoSmithKline has teamed up with US clinical stage biopharmaceutical group iTeos Therapeutics to co-develop and co-commercialise EOS-448, a monoclonal antibody currently in development as a potential treatment for patients with cancer.
Read moreAcivist Elliott backs away from GSK confrontation - report
27th May 2021 10:07
(Sharecast News) - Activist investor Elliott Management will not call for GlaxoSmithKline to sell its vaccines and pharmaceuticals business after taking a big stake in the FTSE 100 drugs company, The Times reported.
Read moreGSK Covid-19 treatment gets emergency approval, vaccine trial progresses
27th May 2021 09:13
(Sharecast News) - GlaxoSmithKline announced on Wednesday that 'sotrovimab' has received emergency use approval in the United States for the treatment of Covid-19, while it also started a global phase 3 study of its Covid-19 vaccine candidate with Sanofi.
Read moreTuesday broker round-up
25th May 2021 13:07
(Sharecast News) - Travis Perkins: Deutsche Bank resumes coverage with a recommendation to hold and a target price of 1,707p.
Read moreEMA gives 'thumbs up' for GSK Covid-19 treatment sotrovimab
21st May 2021 16:11
(Sharecast News) - The European Medicines Agency's Committee for Human Medicinal Products issued a 'positive scientific opinion' for the Covid-19 treatment developed by GlaxoSmithKline and Vir Biotechnology, sotrovimab.
Read moreGlaxoSmithKline reveals positive interim Phase 2 results for Covid-19 vaccine candidate
18th May 2021 08:18
(Sharecast News) - Pharmaceutical company GlaxoSmithKline has revealed positive interim Phase 2 results for its adjuvanted Covid-19 vaccine candidate, developed in partnership with Canadian biopharmaceutical firm Medicago.
Read moreGSK Covid-19 achieves 'strong' results in Phase 2 study
17th May 2021 07:33
(Sharecast News) - GlaxoSmithKline said its Covid-19 vaccine achieved strong results in a Phase 2 study and would start a global Phase 3 study in the next few weeks.
Read moreSunday newspaper round-up: Pfizer, GlaxoSmithKline, Rolls-Royce
16th May 2021 12:25
(Sharecast News) - Pfizer's most senior UK executive has criticised the call to forgo patents on Covid vaccines, warning that it would lead to a global shortage of raw materials. Ben Osborn, who leads the American drugs giant in the UK, said an intellectual-property waiver was "not the answer". "We would see a very rapid short-term impact," he said. "It could allow any organisation to start procuring some of these basic raw materials across multiple countries." Osborn, 44, said it could even mean that existing vaccine manufacturers - which include Astra Zeneca and US biotech venture Moderna - would be unable to fulfil their obligations to deliver doses. - Sunday Times
Read more